Immunology Company Kira Biotech launches with A$20M Series A Funding
Related Articles
-
“Rocket ship” speeds up important research
Featured in ANZAC Institute Discovery, May 2012. Its formal name is the BD Influx Cell Sorter, but to scientists...
-
An answer to cancer
Featured in Burwood Scene, July 3, 2013. Acute Myeloid Leukaemia is a blood cancer. We know it as bone marrow...
-
The cell treatment changing the lives of those living with Glioblastoma
Professor Derek Hart leading Australian research in Dendritic Immunotherapy. Broadcast on Today Tonight Thursday 1 October 2015.
-
Cancer research panel to be formed
Featured in Burwood Scene, February 17, 2015. Are you a cancer patient, survivor of cancer, carer of someone with cancer...
-
Stuck on what to buy your colleague this Christmas for Kris Kringle?
When you have only $10 or $20 to spend, it can sometimes be difficult to find a gift which...
-
Advancing the fight against leukaemia
Featured in ANZAC Institute Discovery, May 2012. Despite substantial advances in treatment options, as many as 60% of patients...
-
There’s a knack to raising funds
Featured in Burwood Scene, June 18, 2014. WITHOUT exception there will be a story in every Burwood Scene promoting...
-
DCR Honours Student has fallen in love with hard work
Kate Chen, promising honours student in the DCR team, wins Concord Hospital Early Career Research Competition. Kate Chen came...
![](mailto:?subject=Immunology Company Kira Biotech launches with A$20M Series A Funding&body=
<img class="aligncenter wp-image-3224 size-medium" src="http://dcresearch.org.au/wp-content/uploads/2019/10/Kira-Biotech-logo-300x150.jpg" alt="" width="300" height="150" /><br />
Brisbane, 29 October 2019: Kira Biotech today announced it has secured Series A funding of A$20 million to develop therapeutics targeting difficult-to-treat immune system disorders.
The round was led by OneVentures, with significant investment from IP Group and support from the Advance Queensland Business Development Fund. The funds will help advance Kira Biotech’s lead candidate KB312 through phase 1 human studies. <a style="color: #ffcc00;" href="https://kirabiotech.com/wp-content/uploads/2019/10/20191024-Kira-Biotech-Series-A-funding-press-release.pdf">Read More</a>
http://dcresearch.org.au/immunology-company-kira-biotech-launches-with-a20m-series-a-funding/){kind=link}